RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Spotlight on Drug Risks

Spotlight on Drug Risks

Posted 01 September 2009

Efforts by the US Food and Drug Administration (FDA) to strengthen risk disclosure and management have intensified, causing the pharmaceutical industry to rethink its approach to advertising and promotional labeling. This article provides an overview of the recent intensified efforts by FDA related to risk information for pharmaceutical drug products.


© 2022 Regulatory Affairs Professionals Society.